药物经济学评价不同钙离子通道阻滞剂在轻中度高血压病人中的应用价值
摘要
目的探讨药物经济学分析不同钙离子通道阻滞剂在轻中度高血压病人中的应用价值。方法选择2014年1月—2016年12月在我院诊治的原发性轻中度高血压病人330例为研究对象,根据治疗药物的不同分为A组、B组、C组,各110例。A组给予左旋氨氯地平治疗,B组给予苯磺酸氨氯地平治疗,C组给予硝苯地平控释片治疗,均连续服药8周,记录治疗效果、不良反应,测定成本-效果。结果 A组、B组、C组完成治疗周期使用药物的平均费用分别为397.14元、441.49元和463.44元。A组、B组、C组的治疗有效率分别为92.7%、92.7%和94.5%,3组治疗总有效率比较差异无统计学意义(P>0.05)。A组、B组、C组治疗期间不良反应发生率分别为9.1%、10.0%和9.1%,差异无统计学意义(P>0.05)。A组、B组、C组的成本-效果比(C/E)分别为4.28、4.76、4.90,增长的成本-效果比(ΔC/ΔE)分别为4.71、5.24、5.39,A组明显低于B组、C组,差异有统计学意义(P<0.05);B组与C组比较差异无统计学意义(P>0.05)。结论左旋氨氯地平为轻中度高血压病人较佳用药方案。
引文
[1] 刘芳,赵临,吴晶.国内钙拮抗剂降压药的药物经济学评价[J].药物评价研究,2016,39(5):875-880.
[2] 罗国金,罗敏,陈小芳,等.四川省彭州市30岁以上居民高血压患病情况及危险因素分析[J].中华预防医学杂志,2016,50(5):404-410.
[3] SCHEY C,KRABBE P F,POSTMA M J,et al.Multi-criteria decision analysis(MCDA):testing a proposed MCDA framework for orphan drugs[J].Orphanet J Rare Dis,2017,12(1):10-14.
[4] 王艳春,吕巧莉,孙建勋.我国2011—2015年降压药药物经济学研究文献系统评价[J].中国药事,2016,30(7):646-654.
[5] MYERSON R M,COLANTONIO L D,SAFFORD M M,et al.Does Identification of previously undiagnosed conditions change care-seeking behavior?[J].Health Serv Res,2017,1(10):913-919.
[6] 董淑杰,李彦,翟所迪.药师在心血管疾病管理中的作用[J].中华心血管病杂志,2016,44(11):998-1000.
[7] GUO J J,CHEN Y,DU W,et al.Antithrombotic therapy and direct medical costs in patients with acute coronary syndrome in Shanghai,China[J].Value Health Reg Issues,2016,9(2):93-98.
[8] 刘艳秋,黄富宏,李爱华.某三级甲等医院高血压老年住院患者抗高血压药物经济学分析[J].中国药业,2016,25(23):23-27.
[9] ?ZYILMAZ A,DE JONG P E,BAKKER S J,et al.Screening for elevated albuminuria and subsequently hypertension identifies subjects in which treatment may be warranted to prevent renal function decline[J].Nephrol Dial Transplant,2016,12(28):1343-1348.
[10] KULCHAITANAROAJ P,BROOKS J M,CHAIYAKUNAPRUK N,et al.Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care[J].J Hypertens,2017,35(1):178-187.
[11] SANCHO-MESTRE C,VIVAS-CONSUELO D,ALVIS-ESTRADA L,et al.Pharmaceutical cost and multimorbidity with type 2 diabetes mellitus using electronic health record data[J].BMC Health Serv Res,2016,16(1):394-398.
[12] 陈勇彬.药学干预社区高血压患者治疗的经济学价值[J].中国药物经济学,2016,11(12):11-14.
[13] AL-RUTHIA Y S,HONG S H,GRAFF C,et al.Examining the relationship between antihypertensive medication satisfaction and adherence in older patients[J].Res Social Adm Pharm,2016,7(9):3129-3133.
[14] PACZKOWSKA A,KOPCIUCH D,NOWAKOWSKA E,et al.Compliance among adolescents with arterial hypertension[J].Adv Clin Exp Med,2016,25(3):441-448.
[15] CHOUDHRY N K,ISAAC T,LAUFFENBURGER J C,et al.Rationale and design of the Study of a Tele-pharmacy Intervention for Chronic diseases to Improve Treatment adherence (STIC2IT):a cluster-randomized pragmatic trial[J].Am Heart J,2016,180(2):90-97.
[16] 刘芳,赵临,吴晶.国内钙拮抗剂降压药的药物经济学评价[J].药物评价研究,2016,39(5):875-880.
[17] BAKRIS G L,BURKART J M,WEINHANDI E D,et al.Intensive hemodialysis,blood pressure,and antihypertensive medication use[J].Am J Kidney Dis,2016,68(5):15-23.
[18] 周丹凤.厄贝沙坦氢氯噻嗪片与苯磺酸氨氯地平片治疗高血压病的疗效及经济学探讨[J].中国医院用药评价与分析,2016,16(6):753-755.
[19] MORFIN J A,FLUCK R J,WEINHANDL E D,et al.Intensive hemodialysis and treatment complications and tolerability[J].Am J Kidney Dis,2016,68(5S1):43-50.
[20] 周长燕.苯磺酸左旋氨氯地平和苯磺酸氨氯地平治疗高血压的效果分析[J].中国现代药物应用,2016,10(13):162-163.
[2] 罗国金,罗敏,陈小芳,等.四川省彭州市30岁以上居民高血压患病情况及危险因素分析[J].中华预防医学杂志,2016,50(5):404-410.
[3] SCHEY C,KRABBE P F,POSTMA M J,et al.Multi-criteria decision analysis(MCDA):testing a proposed MCDA framework for orphan drugs[J].Orphanet J Rare Dis,2017,12(1):10-14.
[4] 王艳春,吕巧莉,孙建勋.我国2011—2015年降压药药物经济学研究文献系统评价[J].中国药事,2016,30(7):646-654.
[5] MYERSON R M,COLANTONIO L D,SAFFORD M M,et al.Does Identification of previously undiagnosed conditions change care-seeking behavior?[J].Health Serv Res,2017,1(10):913-919.
[6] 董淑杰,李彦,翟所迪.药师在心血管疾病管理中的作用[J].中华心血管病杂志,2016,44(11):998-1000.
[7] GUO J J,CHEN Y,DU W,et al.Antithrombotic therapy and direct medical costs in patients with acute coronary syndrome in Shanghai,China[J].Value Health Reg Issues,2016,9(2):93-98.
[8] 刘艳秋,黄富宏,李爱华.某三级甲等医院高血压老年住院患者抗高血压药物经济学分析[J].中国药业,2016,25(23):23-27.
[9] ?ZYILMAZ A,DE JONG P E,BAKKER S J,et al.Screening for elevated albuminuria and subsequently hypertension identifies subjects in which treatment may be warranted to prevent renal function decline[J].Nephrol Dial Transplant,2016,12(28):1343-1348.
[10] KULCHAITANAROAJ P,BROOKS J M,CHAIYAKUNAPRUK N,et al.Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care[J].J Hypertens,2017,35(1):178-187.
[11] SANCHO-MESTRE C,VIVAS-CONSUELO D,ALVIS-ESTRADA L,et al.Pharmaceutical cost and multimorbidity with type 2 diabetes mellitus using electronic health record data[J].BMC Health Serv Res,2016,16(1):394-398.
[12] 陈勇彬.药学干预社区高血压患者治疗的经济学价值[J].中国药物经济学,2016,11(12):11-14.
[13] AL-RUTHIA Y S,HONG S H,GRAFF C,et al.Examining the relationship between antihypertensive medication satisfaction and adherence in older patients[J].Res Social Adm Pharm,2016,7(9):3129-3133.
[14] PACZKOWSKA A,KOPCIUCH D,NOWAKOWSKA E,et al.Compliance among adolescents with arterial hypertension[J].Adv Clin Exp Med,2016,25(3):441-448.
[15] CHOUDHRY N K,ISAAC T,LAUFFENBURGER J C,et al.Rationale and design of the Study of a Tele-pharmacy Intervention for Chronic diseases to Improve Treatment adherence (STIC2IT):a cluster-randomized pragmatic trial[J].Am Heart J,2016,180(2):90-97.
[16] 刘芳,赵临,吴晶.国内钙拮抗剂降压药的药物经济学评价[J].药物评价研究,2016,39(5):875-880.
[17] BAKRIS G L,BURKART J M,WEINHANDI E D,et al.Intensive hemodialysis,blood pressure,and antihypertensive medication use[J].Am J Kidney Dis,2016,68(5):15-23.
[18] 周丹凤.厄贝沙坦氢氯噻嗪片与苯磺酸氨氯地平片治疗高血压病的疗效及经济学探讨[J].中国医院用药评价与分析,2016,16(6):753-755.
[19] MORFIN J A,FLUCK R J,WEINHANDL E D,et al.Intensive hemodialysis and treatment complications and tolerability[J].Am J Kidney Dis,2016,68(5S1):43-50.
[20] 周长燕.苯磺酸左旋氨氯地平和苯磺酸氨氯地平治疗高血压的效果分析[J].中国现代药物应用,2016,10(13):162-163.